Executive Director, Clinical Development

The Executive Director, Clinical Development will play a critical leadership role in advancing our clinical programs in sleep-wake disorders and broader CNS indications. Reporting directly to the Vice President, Clinical Development, this leader will assume primary responsibility for the strategic and operational execution of the company’s late-stage Orexin Receptor 2 Agonist Program (Program 750), which targets narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.